vTv Therapeutics Inc. (VTVT)
| Market Cap | 186.34M |
| Revenue (ttm) | 7.39M |
| Net Income (ttm) | -8.02M |
| Shares Out | 80.64M |
| EPS (ttm) | -0.18 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 13 |
| Last Price | $2.27 |
| Previous Close | $2.31 |
| Change ($) | -0.04 |
| Change (%) | -1.73% |
| Day's Open | 2.35 |
| Day's Range | 2.24 - 2.36 |
| Day's Volume | 1,063,659 |
| 52-Week Range | 1.44 - 4.75 |
vTv Therapeutics (VTVT) delivered earnings and revenue surprises of -50.00% and 23.38%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Awarded Breakthrough Therapy designation for TTP399 for the treatment of type 1 diabetes
vTv Therapeutics, Arrival, PubMatic, and Schrodinger are four up-and-coming stocks to buy. All four are benefiting from rapidly shifting trends.
The FDA bestows a Breakthrough Therapy designation to vTv Therapeutics' (VTVT) TTP399 as an adjunctive therapy to insulin for treating type I diabetes. Shares rise.
Today, VTVT stock is on the move as investors price in a key announcement from the FDA designating a leading drug a breakthrough therapy. The post VTVT Stock: The FDA News Sending vTv Therapeutics Soari...
Designation offers potential for expedited development pathway and reinforces TTP399's potential to provide a substantial clinical benefit Designation offers potential for expedited development pathway ...
HIGH POINT, N.C., April 12, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for typ...
Claims cover methods of reducing HbA1c and the incidence of hypoglycemia using TTP399 in patients with type 1 diabetes Claims cover methods of reducing HbA1c and the incidence of hypoglycemia using TTP3...
HIGH POINT, N.C., March 18, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for typ...
HIGH POINT, N.C., March 08, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for typ...
Initiation of Mechanistic Study of TTP399 expected during Q1 2021
Results found a clinically meaningful decrease in frequency of severe and symptomatic hypoglycemia in addition to statistically significant reductions in HbA1c Results found a clinically meaningful decr...
Phase 1 multiple ascending dose study to evaluate safety of HPP737 in healthy volunteers and inform dose selection for phase 2 planned for 2H 2021
HIGH POINT, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type...
HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer's disease and type 2 ...
Eli Lilly (NYSE: LLY) shares are trading higher on Tuesday after the company announced it will acquire Prevail for total consideration of $26.50 per share in cash. The company also issued the fiscal yea...
HIGH POINT, N.C., Dec. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worl...
Tv Therapeutics (NASDAQ: VTVT) shares were trading higher on Friday after the company said its Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant reduction...
Shares of VTVT stock are taking off on Friday after vTv Therapeutics' parent company purchased 625,000 shares for $1.60 per share. The post VTVT Stock: Why vTv Therapeutics Is Soaring on Friday appeared...
As of late, it has definitely been a great time to be an investor in vTv Therapeutics (VTVT).
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 817 ...
HIGH POINT, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced it has entered into a common stock purchase agreement (“Purchase Agreement”) for up to $47 millio...
With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 Biotech Pe...
HIGH POINT, N.C., Nov. 05, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the third quarter ended September 30, 2020, and provided an update on the pro...
HIGH POINT, N.C., Nov. 04, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today reported baseline characteristics for the enrolled subjects in the ongoing Elevage clinical study of azelir...
HIGH POINT, N.C., Oct. 29, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will make an oral presentation at the 13th Clinical Trials on Alzheimer's Disease (CTAD) ...
Data Reported at EASD Virtual Conference Demonstrate that TTP399 Did Not Increase Plasma or Urine Ketones, Avoiding a Key Limitation to the Development of Oral Adjunctive Therapies for T1D Data Reported...
HIGH POINT, N.C., Sept. 15, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) announced the appointment of Edward P. Taibi, Executive Vice President of MacAndrews & Forbes Incorporated (...
A handful of pharmaceutical stocks have been on fire lately, but I'm writing for a "buy" prescription for five of the best names now.
HIGH POINT, N.C., Aug. 03, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the second quarter ended June 30, 2020, and provided an update on the pro...
HIGH POINT, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc . (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer's Association International Con...
- Treatment with TTP399 resulted in significant improvements in HbA1c with reduction in insulin, without increasing risk of hypoglycemia or diabetic ketoacidosis (DKA) -
HIGH POINT, N.C., May 22, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that it will host its 2020 Annual Meeting of Stockholders (the "Annual Meeting") as a virtual-o...
Is (VTVT) Outperforming Other Medical Stocks This Year?
As of late, it has definitely been a great time to be an investor in vTv Therapeutics Inc. (VTVT).
Company Announced Positive Results from Its Phase 2 Type 1 Diabetes Trial Showing that TTP399 Lowered HbA1C, Decreased the Use of Insulin for Patients and Increased Time in Range Company Announced Posit...
Steve Holcombe transitioned from telecom to biotech back when vTv Therapeutics Inc (NASDAQ: VTVT) was just a startup.
vTv Therapeutics: A Promising Small Molecule Drug Discovery Pick For 2020
Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.
Shares of micro-cap biotech vTv Therapeutics Inc (NASDAQ: VTVT) were advancing to their highest level since October 2018 Monday following a clinical readout from the company.
These drug stocks all have tremendous potential as these small companies work to treat widespread diseases in the U.S. and beyond.
vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 9.09% and -99.53%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Here we discuss six small-cap companies with promising candidates in their pipeline for Alzheimer's disease.
Patients treated with TTP399 had improved Time in Range (TIR), reduced time in hyperglycemia, fewer hypoglycemic events, and lower bolus insulin dose Patients treated with TTP399 had improved Time in Ra...
The thinly traded micro-cap biotech vTv Therapeutics Inc (NASDAQ: VTVT) is on investors' radars ahead of a Sept.
Presenting New Clinical Data from Phase 2 Study in Type 1 Diabetes with Liver Selective GKA Program
HIGH POINT, N.C., Sept. 04, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
The GuruFocus All-in-One Screener can be used to find insider trades from the past week.
vTv Therapeutics is currently trading at a super low stock price, indicating a potential buy for a high risk/return.
About VTVT
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates to fill unmet medical needs. The company is developing TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant PDE4 inhibitor that addresses inflammatory diseases. It is also involved in the clinical development of other programs, including a small molecule GLP-1r agonist; the PD... [Read more...]
| Industry Biotechnology | IPO Date Jul 30, 2015 |
| CEO Stephen Holcombe | Employees 25 |
| Stock Exchange NASDAQ | Ticker Symbol VTVT |
Financial Performance
In 2020, VTVT's revenue was $6.41 million, an increase of 132.05% compared to the previous year's $2.76 million. Losses were -$8.50 million, -34.84% less than in 2019.
Analyst Forecasts
According to 2 analysts, the average rating for VTVT stock is "Buy." The 12-month stock price forecast is 6.75, which is an increase of 197.36% from the latest price.